Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT

This study showed that treating critically ill COVID-19 patients with anti-clotting drugs significantly reduced the number of clotting complications. This is important because it is a discovery of a critical treatment consideration for COVID-19 patients which can reduce the number of blood clots while in the hospital, significantly improving survival outcomes. Edy Kim is funded by the Lung Association Dalsemer Award for his work in interstitial lung disease.